Singapore, Nov. 12 -- C2N Diagnostics, LLC and LSI Medience Corporation (LSIM) have announced a strategic partnership to pursue regulatory approval and commercialisation of PrecivityAD2(R) in Japan, following the test's recent US FDA clearance. The collaboration combines C2N's expertise in high-resolution mass spectrometry and Alzheimer's diagnostics with LSIM's established clinical laboratory, regulatory and commercial capabilities in Japan.

In the United States, PrecivityAD2(R) is FDA cleared for adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other forms of cognitive decline. The test is intended to be used in conjunction with clinical assessmen...